Ghana approves Oxford’s malaria vaccine for children aged 5 to 36 months
BMJ 2023 ; 381 doi: https://doi.org/10.1136/bmj.p850 (Published 14 April 2023) Cite this as: BMJ 2023;381:p850
- Elisabeth Mahase
- The BMJ
Ghana’s Food and Drugs Authority (FDA) has approved a malaria vaccine developed by the University of Oxford for use in children aged 5 months to 3 years.
Manufactured by the Serum Institute of India, the R21/Matrix-M malaria vaccine contains the circumsporozoite protein, secreted by the malaria parasite, fused to hepatitis B surface antigen, and delivered alongside Novavax’s Matrix-M adjuvant, which stimulates the entry of antigen presenting cells …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42
(
excludes VAT
)
You can download a PDF version for your personal record.